Christina Wenglén Selected Research

5-HT2B Serotonin Receptor

12/2020	Pathological Insight into 5-HT2B Receptor Activation in Fibrosing Interstitial Lung Diseases.
1/2018	Pulmonary fibrosis in vivo displays increased p21 expression reduced by 5-HT2B receptor antagonists in vitro - a potential pathway affecting proliferation.
1/2016	5-HT2B receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christina Wenglén Research Topics

Disease

3	Pulmonary Fibrosis (Fibrosing Alveolitis) 12/2020 - 01/2016
2	Fibrosis (Cirrhosis) 01/2018 - 01/2016
1	Rheumatoid Arthritis 12/2020
1	Systemic Scleroderma (Systemic Sclerosis) 12/2020
1	Interstitial Lung Diseases (Interstitial Lung Disease) 12/2020
1	Lung Diseases (Lung Disease) 01/2018
1	Nephritis 01/2015
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2015
1	Autoimmune Diseases (Autoimmune Disease) 01/2015

Drug/Important Bio-Agent (IBA)

5	Serotonin (5 Hydroxytryptamine)IBA 12/2020 - 01/2015
3	5-HT2B Serotonin ReceptorIBA 12/2020 - 01/2016
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2018 - 01/2016
1	DecorinIBA 01/2016
1	CollagenIBA 01/2016
1	Isoflurane FDA LinkGeneric 01/2016
1	Interferon Type IIBA 01/2015
1	anti-dsDNA autoantibodyIBA 01/2015

Therapy/Procedure

1	Anesthesia 01/2016